Bright Green Corporation reported no revenues and a net loss of $2.6 million for Q1 2023, which is in line with expectations. The company is focused on scaling operations and becoming a leading federally authorized medical cannabis supplier in the US. While the results show that the company is still in the early stages of development, the focus on scaling operations and securing its position in the market could lead to potential growth in the future. However, the short-term impact on the stock price is likely to be neutral as the results are in line with expectations.